Cargando…

Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole

PURPOSE: To analyze the combined effect of CYP2C19 genetic polymorphism and PPIs coadministration on voriconazole trough concentration (VCZ-C(trough)) in Chinese patients with hematological disorders. PATIENTS AND METHODS: A prospective observational study involved 250 plasma samples from 114 adult...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mafuru, Magesa, Wu, Sanlan, Mayala, Henry, Msengwa, Zaituni, Phillip, Amani, Mgone, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572102/ https://www.ncbi.nlm.nih.gov/pubmed/34754219 http://dx.doi.org/10.2147/PGPM.S329662

Ejemplares similares

The effect of inflammation on voriconazole trough concentrations in children
por: ter Avest, Mendy, et al.
Publicado: (2016)

Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children
por: Zhao, Yi-Chang, et al.
Publicado: (2021)

Interactive Effects of Glucocorticoids and Cytochrome P450 Polymorphisms on the Plasma Trough Concentrations of Voriconazole
por: Jia, Su-jie, et al.
Publicado: (2021)

Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients
por: Zhao, Yi‐Chang, et al.
Publicado: (2020)

Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole
por: Hall, Victoria G, et al.
Publicado: (2023)

Moderate correlation between systemic IL‐6 responses and CRP with trough concentrations of voriconazole
por: Vreugdenhil, Bas, et al.
Publicado: (2018)

Remission of hepatotoxicity in chronic pulmonary aspergillosis patients after lowering trough concentration of voriconazole
por: Teng, Guo-Jie, et al.
Publicado: (2020)

Factors influencing left ventricular ejection fraction in patients with coronary microvascular disease and obstructive coronary artery disease
por: Mayala, Henry Anselmo, et al.
Publicado: (2020)

Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis
por: Jin, Haiying, et al.
Publicado: (2016)

Association of Voriconazole Trough Plasma Concentration with Efficacy and Incidence of Hepatotoxicity in Iranian Patients with Hematological Malignancies
por: Taghvaye-masoumi, Hamidreza, et al.
Publicado: (2021)

The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment
por: Tanaka, Mizue, et al.
Publicado: (2014)

The association of (18)F-FDG PET/CT and biomarkers in confirming coronary microvascular dysfunction
por: Mayala, Henry Anselmo, et al.
Publicado: (2018)

Predictors of Voriconazole Trough Concentrations in Patients with Child–Pugh Class C Cirrhosis: A Prospective Study
por: Zhao, Yichang, et al.
Publicado: (2021)

Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data
por: Bolcato, Léa, et al.
Publicado: (2021)

Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients
por: Ebrahimpour, Sholeh, et al.
Publicado: (2017)

Application of Population Pharmacokinetic Analysis to Characterize CYP2C19 Mediated Metabolic Mechanism of Voriconazole and Support Dose Optimization
por: Li, SiChan, et al.
Publicado: (2022)

Decrease of voriconazole trough levels during therapy with enteral nutrition: a case report
por: Kaneko, Hiromi, et al.
Publicado: (2022)

Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study
por: Suetsugu, Kimitaka, et al.
Publicado: (2021)

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors
por: Sharma, Shringi, et al.
Publicado: (2022)

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
por: Shi, Hui-Yan, et al.
Publicado: (2010)

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
por: Gardin, Anne, et al.
Publicado: (2018)

Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation
por: Suetsugu, Kimitaka, et al.
Publicado: (2019)

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
por: Azuma, Junichi, et al.
Publicado: (2011)

Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer
por: Ozeki, Tomoko, et al.
Publicado: (2019)

The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma
por: Liu, Xin, et al.
Publicado: (2022)

Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis
por: Kim, Jung Sun, et al.
Publicado: (2023)

Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children
por: Espinoza, N., et al.
Publicado: (2019)

Favorable Effects of Voriconazole Trough Concentrations Exceeding 1 μg/mL on Treatment Success and All-Cause Mortality: A Systematic Review and Meta-Analysis
por: Hanai, Yuki, et al.
Publicado: (2021)

Generalized exfoliative skin rash as an early predictor of supratherapeutic voriconazole trough levels in a leukemic child: A case report
por: Amanati, Ali, et al.
Publicado: (2020)

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism
por: Gao, Nanyong, et al.
Publicado: (2022)

Factors influencing plasma concentration of voriconazole and voriconazole- N-oxide in younger adult and elderly patients
por: Cheng, Lin, et al.
Publicado: (2023)

ANTIBACTERIAL EFFECTS OF SINGLE AND COMBINED CRUDE EXTRACTS OF SYNADENIUM GLAUCESCENS AND COMMIPHORA SWYNNERTONII
por: Mary, Ochollah G., et al.
Publicado: (2022)

CYP51A1 polymorphism and voriconazole-associated hepatotoxicity in children undergoing hematopoietic cell transplant
por: Takahashi, Takuto, et al.
Publicado: (2021)

Elevated Vancomycin Trough Concentration: Increased Efficacy and/or Toxicity?
por: Elyasi, Sepideh, et al.
Publicado: (2014)

Clinical and genetic determinants of nevirapine plasma trough concentration
por: Giacomelli, Andrea, et al.
Publicado: (2018)

Coadministration of Pinellia ternata Can Significantly Reduce Aconitum carmichaelii to Inhibit CYP3A Activity in Rats
por: Wu, Jinjun, et al.
Publicado: (2014)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
por: El Rouby, Nihal, et al.
Publicado: (2018)

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
por: Chung, Hyewon, et al.
Publicado: (2015)

Oxandrolone Coadministration Does Not Alter Plasma Propranolol Concentrations in Severely Burned Pediatric Patients
por: Guillory, Ashley N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aifadn78j4o6dcfuv9vbkdi8nk